Liver Cancer Clinical Trials

A listing of Liver Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 62 clinical trials
Futibatinib and Pembrolizumab for the Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A B or C Liver Cancer

This phase II trial studies the effect of futibatinib and pembrolizumab in treating patients with FGF19 positive BCLC stage A, B, or C liver cancer that has spread to other parts of the body

  • 18 Sep, 2021
  • 1 location
Magnetic Resonance-guided Adaptive Stereotactic Body Radiotherapy for Hepatic Metastases

Stereotactic body radiotherapy (SBRT) is an established local treatment method for patients with hepatic oligometastases. Liver metastases often occur in close proximity to radiosensitive organs at risk (OARs). This limits the possibility to apply sufficiently high doses needed for optimal local control. MR-guided radiotherapy (MRgRT) is expected to hold potential …

  • 06 Sep, 2021
  • 1 location
A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma

This is a multicenter, open-label, dose-escalation study designed to determine the maximum tolerated dose (MTD) by evaluating dose-limiting toxicities (DLTs) and to evaluate the safety, tolerability, pharmacokinetics, anti-tumor effect, and biomarkers of ERY974 in combination with atezolizumab and bevacizumab following premedication with tocilizumab in patients with locally advanced or metastatic …

  • 03 Sep, 2021
  • 3 locations
This Study is to Evaluate OBI-3424 Safe and Effective Treatment Dose in Subjects With Hepatocellular Carcinoma or Castrate Resistant Prostate Cancer

A first-in-human open-label, Phase I/II study to evaluate the safety, tolerability, MTD/RP2D, PK, and preliminary efficacy of OBI-3424 administered as a single agent in patients with solid tumors, hepatocellular carcinomas (HCC), and castrate-resistant prostate cancer (CRPC).

renal function
measurable disease
kidney function test
  • 15 Sep, 2021
  • 2 locations
Pilot 3D Contrast-Enhanced Ultrasound Imaging to Predict Treatment Response in Liver Metastases

Patients are invited to participate in a research study of liver perfusion (how blood flows to the liver over time). Researchers hope to learn whether perfusion characteristics of liver metastases may be predictive of response to treatment and whether liver perfusion characteristics can be used to follow response to treatment. …

liver metastasis
treatment regimen
  • 07 Sep, 2021
  • 1 location
Nivolumab (Anti-PD1) Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

Background A most common liver cancer in adults is hepatocellular carcinoma. Other kinds of liver cancer happen when colorectal or pancreatic cancer spreads to the

neutrophil count
hepatocellular carcinoma
liver cancer
measurable disease
  • 12 Sep, 2021
  • 1 location
Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients

with Barcelona Clinic Liver Cancer (BCLC) stage A, B1, B2, and C. SIR-Spheres consist of biocompatible resin microspheres containing yttrium-90 (Y-90), with a size between 20 and 60 microns in

  • 08 Sep, 2021
  • 3 locations
TCR-engineered T Cells in Solid Tumors: IMA202-101

The study purpose is to establish the safety and tolerability of IMA202 product in patients with solid tumors that express melanoma-associated antigen 1 (MAGEA1).

hepatocellular carcinoma
metastatic malignant solid tumor
measurable disease
bone marrow procedure
solid tumor
  • 15 Sep, 2021
  • 16 locations
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

A Phase 1 dose escalation and expansion study evaluating safety, tolerability and pharmacokinetics of PF-06952229 in adult patients with advanced solid tumors.

neutrophil count
breast cancer
bone metastases
measurable disease
  • 17 Sep, 2021
  • 23 locations
Study of INCB086550 in Select Solid Tumors

An open-label, nonrandomized study to evaluate the efficacy and safety of INCB086550, a first-in-class oral inhibitor of PD-L1, as initial immune checkpoint inhibitor therapy in participants with select solid tumors

lung cancer
programmed cell death 1 ligand 1
measurable disease
  • 10 Sep, 2021
  • 11 locations